Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer

Oncologist

Volumn 13, Issue 12, 2008, Pages 1224-1234

  Lenihan, Daniel J ^a   Esteva, Francisco J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Adverse events; Aromatase inhibitors; Chemotherapy; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; CARVEDILOL; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; LETROZOLE; METHOTREXATE; PACLITAXEL; PLACEBO; RAZOXANE; TAMOXIFEN; TRASTUZUMAB; VALSARTAN;

ANGINA PECTORIS; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; EARLY CANCER; FOLLOW UP; HEALTH CARE PERSONNEL; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIA; ISCHEMIC HEART DISEASE; LEUKEMIA; LONG TERM CARE; MASTECTOMY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STROKE; SYSTEMIC THERAPY; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; NEOPLASM STAGING; RADIOTHERAPY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 58749104543     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0112     Document Type: Review

References (80)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast cancer. v. 1.2007. Available at http://www. nccn.org/professionals/physician-gls/PDF/breast.pdf, accessed January 4, 2007.
2. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007;25:4952-4960.
3. Fleissig A, Jenkins V, Catt S et al. Multidisciplinary teams in cancer care: Are they effective in the UK? Lancet Oncol 2006;7:935-943.
4. Giordano SH, Kuo YF, Freeman JL et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005;97:419-424.
5. Yeh ET, Tong AT, Lenihan DJ et al. Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation 2004; 109:3122-3131.
6. Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-4115.
7. Jones LW, Haykowsky MJ, Swartz JJ et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435-1441.
8. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-650.
9. Herrington DM, Reboussin DM, Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.
10. Hsia J, Langer RD, Manson JE et al. Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Arch Intern Med 2006; 166:357-365.
11. Grady D, Herrington D, Bittner V et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
12. Roychoudhuri R, Robinson D, Putcha V et al. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: A population-based study. BMC Cancer 2007;7:9.
13. Correa CR, Litt HI, Hwang WT et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 2007;25:3031-3037.
14. Harris EE, Correa C, Hwang WT et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 2006;24:4100-4106.
15. Patt DA, Goodwin JS, Kuo YF et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 2005;23:7475-7482.
16. Hooning MJ, Botma A, Aleman BM et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007;99: 365-375.
17. Harris EE. Cardiac mortality and morbidity after breast cancer treatment. Cancer Control 2008;15:120-129.
18. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998; 352:930-942.
19. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365:1687-1717.
20. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.
21. Ryberg M, Nielsen D, Skovsgaard T et al. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998; 16:3502-3508.
22. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
23. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003;97:2869-2879.
24. Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer. Available at http://www.clinicaltrials.gov/ ct2/show/NCT00087178, accessed October 10, 2008.
25. Combination Chemotherapy in Treating Women With Breast Cancer. Available at http://www.clinicaltrials.gov/ct2/show/NCT00041119, accessed October 10, 2008.
26. Perez EA. TAC - a new standard in adjuvant therapy for breast cancer? N Engl J Med 2005;352:2346-2348.
27. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: Is our ear really to the ground? J Clin Oncol 2008;26:1201-1203.
28. Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-2754.
29. Lenihan DJ, Massey MR, Baysinger KB et al. Superior detection of cardiotoxicity during chemotherapy using biomarkers [abstract]. J Cardiac Fail 2007;13:S151.
30. Ekstein S, Nir A, Rein AJ et al. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol 2007;29:440-444.
31. Lenihan DJ, Massey MR, Baysinger K et al. Early detection of cardiotoxicity during chemotherapy using biomarkers [abstract]. J Clin Oncol 2007; 25:19521.
32. Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-2262.
33. Carver JR, Schuster SJ, Glick JH. Doxorubicin cardiotoxicity in the elderly: Old drugs and new opportunities. J Clin Oncol 2008;26:3122-3124.
34. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-2481.
35. Nakamae H, Tsumura K, Terada Y et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005;104:2492-2498.
36. Tebbi CK, London WB, Friedman D et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007;25:493-500.
37. Cardinale D. Reply to Letter to the Editor "Troponin I, cardiac ventricular dysfunction and causal toxicity of chemotherapy drugs", by L. Delval (Ann Oncol 2002;13: 1952-1953). Ann Oncol 2002;13:1952-1953.
38. Lipshultz SE. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol 1996;14:328-331.
39. Jones SE, Savin MA, Holmes FA et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381-5387.
40. Jones S, Holmes F, O'Shaughnessy J et al. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: Docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/ cyclophosphamide and is well-tolerated in women 65 or older [abstract]. Breast Cancer Res Treat 2007;106:S5.
41. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-1221.
42. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-7826.
43. Rastogi P, Jeong J, Geyer CE et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC) paclitaxel (T) vs. AC T with trastuzumab (H). J Clin Oncol 2007;25:LBA513.
44. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-7819.
45. Perez EA, Suman VJ, Davidson NE et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231-1238.
46. Halyard MY, Pisansky TM, Solin LJ et al. Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group phase III trial N9831 [abstract]. J Clin Oncol 2006;24:523.
47. Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007;25: 3859-3865.
48. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
49. Ewer MS, Lenihan DJ. Is trastuzumab associated with adverse cardiac effects in patients with breast cancer? Nat Clin Pract Oncol 2008;5:192-193.
50. Kutteh LA, Hobday T, Jaffe A et al. A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer [abstract]. J Clin Oncol 2007;25:579.
51. Godkar D, Bachu K, Dave B et al. Comparison and co-relation of invasive and noninvasive methods of ejection fraction measurement. J Natl Med Assoc 2007;99:1227-1228, 1231-1234.
52. Sengupta PP, Northfelt DW, Gentile F et al. Trastuzumab-induced cardiotoxicity: Heart failure at the crossroads. Mayo Clin Proc 2008;83:197-203.
53. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 2005;23:2900-2902.
54. Grey AB, Stapleton JP, Evans MC et al. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995;80:3191-3195.
55. Buzdar A, Chlebowski R, Cuzick J et al. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin 2006;22:1575-1585.
56. Braithwaite RS, Chlebowski RT, Lau J et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18: 937-947.
57. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
58. Buzdar A, Howell A, Cuzick J et al.; ATAC Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633-643.
59. Coates AS, Keshaviah A, Thürlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007;25:486-492.
60. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97: 1262-1271.
61. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study):Arandomised controlled trial. Lancet 2007;369: 559-570.
62. Baum M, Budzar AU, Cuzick J et al.; ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359:2131-2139.
63. Forbes JF, Cuzick J, Buzdar A et al.; ATAC Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53.
64. Mouridsen H, Keshaviah A, Coates AS et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 Trial. J Clin Oncol 2007;25:5715-5722.
65. Coombes RC, Hall E, Gibson LJ et al.; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092.
66. National Institutes of Health. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III Final Report). Available at http://www.nhlbi.nih.gov/guidelines/cholesterol/ atp3-rpt.htm, accessed May 1, 2007.
67. Hozumi Y, Kawano M, Saito T et al. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 1998;83:1633-1635.
68. Sawada S, Sato K, Kusuhara M et al. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer. Acta Oncol 2005;44:134-141.
69. Wojtacki J, Lesniewski-Kmak W, Pawlak W et al. Anastrozole therapy and lipid profile: An update [abstract]. Eur J Cancer Suppl 2004;2:142.
70. Markopoulos C, Chrissochou M, Michailidou A et al. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: Preliminary results of the ATENA substudy. Anticancer Drugs 2005;16:879-883.
71. McCloskey E, Eastell R, Lakner G et al. Initial results from the LEAP study: The first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Presented at the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8-11, 2005.
72. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
73. Manson JE, Hsia J, Johnson KC et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
74. Rosamond W, Flegal K, Friday G et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-e171.
75. Lenihan DJ. Tyrosine kinase inhibitors: Can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork? J Clin Oncol 2008;26:5154-5155.
76. Forrest LM, McMillan DC, McArdle CS et al. An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 2005;93: 977-978.
77. Birchall M, Bailey D, King P; South West Cancer Intelligence Service Head and Neck Tumour Panel. Effect of process standards on survival of patients with head and neck cancer in the south and west of England. Br J Cancer 2004;91:1477-1481.
78. Stephens MR, Lewis WG, Brewster AE et al. Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer. Dis Esophagus 2006;19:164-171.
79. Yusuf S, Reddy S, Ounpuu S et al. Global burden of cardiovascular diseases: Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746-2753.
80. Forbes JF, Cuzick J, Buzdar A et al. for The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53.